Menu
11/04/2014
Prostate Cancer Tests Not Accurate Enough
Prostate cancer in some men is being allowed to progress to a dangerous stage because tests are not accurate enough, according to the Cancer Research UK Cambridge Institute.
The study, published in the British Journal of Cancer, suggest that men are being given false hopes after it found that more than half of a group of men whose tumours were classified as slow-growing turned out later to be a serious form of the disease.
Each year around 41,700 men in the UK are diagnosed with this cancer and 10,800 of them die from the illness.
The findings generate doubts on a widely used strategy of “active surveillance” after it was found that some of the test fail to precisely rate how dangerous the cancer could be.
Biopsy samples examined under a microscope are used to rate how aggressive a prostate cancer is, referring to its grade and how far it has spread.
For the research the Cambridge scientists compared the staging and grading of more than 800 men' s cancers before and after they had surgery to remove their prostate, and they found that out of 415 of patients whose cancer had been classified as slow-growing and confined to the prostate, just over a quarter (209) were found to have a more aggressive disease than originally thought, and 131 had cancers that had spread beyond the prostate gland.
Professor Malcolm Mason, Cancer Research UK's prostate cancer specialist, said: "We need better methods of assigning a grade and stage so that no man has to unnecessarily undergo treatment, while at the same time making sure we detect and treat the cancers that really need it."
(CVS/MH)
The study, published in the British Journal of Cancer, suggest that men are being given false hopes after it found that more than half of a group of men whose tumours were classified as slow-growing turned out later to be a serious form of the disease.
Each year around 41,700 men in the UK are diagnosed with this cancer and 10,800 of them die from the illness.
The findings generate doubts on a widely used strategy of “active surveillance” after it was found that some of the test fail to precisely rate how dangerous the cancer could be.
Biopsy samples examined under a microscope are used to rate how aggressive a prostate cancer is, referring to its grade and how far it has spread.
For the research the Cambridge scientists compared the staging and grading of more than 800 men' s cancers before and after they had surgery to remove their prostate, and they found that out of 415 of patients whose cancer had been classified as slow-growing and confined to the prostate, just over a quarter (209) were found to have a more aggressive disease than originally thought, and 131 had cancers that had spread beyond the prostate gland.
Professor Malcolm Mason, Cancer Research UK's prostate cancer specialist, said: "We need better methods of assigning a grade and stage so that no man has to unnecessarily undergo treatment, while at the same time making sure we detect and treat the cancers that really need it."
(CVS/MH)
Related UK National News Stories
Click here for the latest headlines.
25 September 2009
Screening For Prostate Cancer 'Remains Controversial'
There is not enough evidence to support routine prostate cancer screening. Two papers published on bmj.com today conclude that there is insufficient evidence to support population-wide screening for prostate cancer using the prostate specific antigen (PSA) test.
Screening For Prostate Cancer 'Remains Controversial'
There is not enough evidence to support routine prostate cancer screening. Two papers published on bmj.com today conclude that there is insufficient evidence to support population-wide screening for prostate cancer using the prostate specific antigen (PSA) test.
16 May 2012
New Info Revises Opinion On Cancer Drug
A prostate cancer drug should be given to NHS patients, a health watchdog has said. The National Institute for Health and Clinical Excellence (Nice) revised its recommendations on the drug Abiratone after fresh information from the manufacturer, Janssen. Experts have welcomed the draft guidance.
New Info Revises Opinion On Cancer Drug
A prostate cancer drug should be given to NHS patients, a health watchdog has said. The National Institute for Health and Clinical Excellence (Nice) revised its recommendations on the drug Abiratone after fresh information from the manufacturer, Janssen. Experts have welcomed the draft guidance.
24 May 2005
Trials for prostate cancer drugs announced
Scientists have announced that they are testing new drugs that could be used to treat advanced prostate cancer. Currently, advanced prostate cancer is treated with hormone therapy. However, this only works for a short period of time, after which there are few other options for the patient, apart from palliative care.
Trials for prostate cancer drugs announced
Scientists have announced that they are testing new drugs that could be used to treat advanced prostate cancer. Currently, advanced prostate cancer is treated with hormone therapy. However, this only works for a short period of time, after which there are few other options for the patient, apart from palliative care.
09 November 2004
Report highlights successful fight against prostate cancer
Men with prostate cancer are being seen more quickly and receiving better care according to a new report out today. The report sets out progress made following the publication of the NHS Prostate Cancer programme four years ago.
Report highlights successful fight against prostate cancer
Men with prostate cancer are being seen more quickly and receiving better care according to a new report out today. The report sets out progress made following the publication of the NHS Prostate Cancer programme four years ago.
31 October 2005
Call for action on prostate cancer
The leaders of the three main political parties have issued a joint call for greater action to tackle the problem of prostate cancer. Prime Minister Tony Blair, Conservative leader Michael Howard and Liberal Democrat leader Charles Kennedy have all recorded messages of support for the Prostate Cancer Charter for Action.
Call for action on prostate cancer
The leaders of the three main political parties have issued a joint call for greater action to tackle the problem of prostate cancer. Prime Minister Tony Blair, Conservative leader Michael Howard and Liberal Democrat leader Charles Kennedy have all recorded messages of support for the Prostate Cancer Charter for Action.
-
Northern Ireland WeatherThis Evening and Tonight:Rain clearing away east by early evening with some clear spells but a few showers likely to affect the North coast and other areas towards dawn, remaining breezy and mild overnight. Minimum temperature 9 °C.
